REVELATION BIOSCIENCES, INC.

Revelation Biosciences, Inc. (Nasdaq: REVB) is a clinical-stage biotechnology company focused on immunology, with an emphasis on mucosal immune system research and the development of novel therapeutics and diagnostics. The company entered the public markets through its merger with Petra Acquisition Corp., a blank-check company sponsored by Petra Sponsor LLC, which completed its SPAC IPO in 2021. The business combination closed in 2022, bringing REVB into the life sciences sector of the public SPAC landscape. The company filed an 8-K with the SEC on June 24, 2026, reflecting continued reporting obligations as a publicly traded entity. For complete filing history, deal terms, and real-time SPAC data on REVB, sign up for full access at SpacDesk.